Search | Clinical Trials Finder

Conditions: Hepatocellular Carcinoma
Interventions: Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Prescott Valley, Arizona • Springdale, Arkansas • Los Angeles, California + 15 more

Conditions: Advanced Solid Tumors
Interventions: Venetoclax, Rovalpituzumab Tesirine, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 5
States / cities: La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more

Conditions: Urothelial Carcinoma
Interventions: Livmoniplimab, Budigalimab, Docetaxel, Paclitaxel, Gemcitabine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Springdale, Arkansas • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Small Cell Lung Cancer
Interventions: ABBV-011, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Springdale, Arkansas • Sacramento, California + 16 more

Conditions: Advanced Solid Tumors Cancer
Interventions: Livmoniplimab, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 16 more

Conditions: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer
Interventions: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 18
States / cities: Duarte, California • Irvine, California • Chicago, Illinois + 14 more

Conditions: Head and Neck Cancer
Interventions: ABBV-181, ABBV-368, ABBV-927; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas

Conditions: Human Immunodeficiency Virus (HIV), HIV Infection, HIV-1
Interventions: ABBV-181, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 15
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 11 more

Conditions: Hepatocellular Carcinoma
Interventions: Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 13
States / cities: Duarte, California • Irvine, California • Orange, California + 9 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-368, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: La Jolla, California • Sacramento, California • Stanford, California + 7 more

Conditions: Human Immuno-deficiency Virus (HIV) Disease
Interventions: Budigalimab, Placebo for Budigalimab, ABBV-382, Placebo for ABBV-382; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors
Interventions: ABBV-927, ABBV-368, ABBV-181, Carboplatin, Nab-paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 13
States / cities: Springdale, Arkansas • Santa Rosa, California • New Haven, Connecticut + 10 more

Conditions: Cancer
Interventions: SC-004, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 12
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Duarte, California + 9 more

Conditions: Solid Tumor, Adult
Interventions: TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6, TTX-030 and budigalimab, TTX-030, budigalimab, nab-paclitaxel and gemcitabine, TTX-030 and pembrolizumab, TTX-030, nab-paclitaxel and gemcitabine, Budigalimab and mFOLFOX6; Combination Product
Lead sponsor: Trishula Therapeutics, Inc.; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 21 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: Budigalimab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Bakersfield, California • Los Angeles, California • San Francisco, California + 5 more

Conditions: Advanced Squamous Tumors
Interventions: ABBV-711, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 6
States / cities: Duarte, California • Irvine, California • Chicago, Illinois + 3 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 840 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 19
States / cities: La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more

Conditions: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions: Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Santa Monica, California + 5 more

Conditions: Advanced Solid Tumors
Interventions: paclitaxel, FOLFIRI, ABT-165, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 6 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-368, Tilsotolimod, Nab-paclitaxel, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Chicago, Illinois • Louisville, Kentucky • Detroit, Michigan + 5 more

Conditions: Ovarian Cancer
Interventions: SC-003, SC-003 in combination with ABBV-181; Drug
Lead sponsor: Stemcentrx; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Duarte, California • Chicago, Illinois + 12 more

Conditions: Solid Tumors
Interventions: ABBV-303, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 7 more

Conditions: Pancreatic Cancer
Interventions: ABBV-927, Budiglimab, modified FOLFIRINOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: Advanced Solid Tumors
Interventions: ABBV-706, Cisplatin, Budigalimab, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Gilbert, Arizona • Duarte, California • Irvine, California + 18 more

Search by objective public record fields.

Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

A Study of ABT-165 in Subjects With Solid Tumors

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors